34
nanotimes
Companies
Facts
R
USNANO’s net profit in 2009 totaled 11.25 billion rubles ($368.6 million). The Corporation’s
net profit in the reporting period resulted mostly from income received on deposit of temporary available funds as recommended by the Ministry of Finance of the Russian Federation. RUSNANO’s independent investment income in the reporting period reached 13.53 billion rubles ($443.3 million). The corporation’s before-tax income in 2009 totaled 14.07 billion rubles ($461 million). The spending of the Corporation in 2009, including the returned amount of the asset contribution, totaled 106.94 billion rubles ($3.5039 billion), which is below the estimated levels.
Furthermore, Standard & Poor’s expects strong on- going state support to be provided to Russian Cor- poration of Nanotechnologies in the next few years. The agency expects a “high” probability of extraordi- nary timely government support if necessary. There- fore the outlook on RUSNANO was revised to stable from negative and affirmed the ‚BB+‘ long-term, ‚B‘ short-term, and ‚ruAA+‘ national scale ratings on RUSNANO.
http://www.rusnano.com
G
erman company sarastro has introduced a new technology for controlled release of active sub-
stances. It allows to equip compounds and coatings with biocides, flavours, scents or drugs in such a way that they are not released to the environment straight away but only at the time the substance is needed. sarastro is specialized in the development and mar- keting of biologically active surface functions.
http://www.sarastro-nanotec.com
S
electa Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vac-
cines, has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture
Partners, Flagship Ventures, NanoDimension and
Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million. Proceeds from the Series C financing will be used to expand Selecta’s development of a new class of synthetic vaccines for prophylactic and therapeutic indications based on the company’s proprietary targeted Synthetic Vac- cine Particle (tSVP™) platform. The company’s lead product candidate will enter first-in-human clinical evaluation in 2011. The tSVP platform is based on
biodegradable polymeric nanoparticles that fully-
integrate all the vaccine components for targeting to immune cells for optimal cellular or humoral immune response.
http://www.selectabio.com
S
hocking Technologies, an embedded ESD solutions company, raised an additional $5.2 mil-
lion in its B-1 round completing the round at $13.2 million. The money will be used to speed the build out of manufacturing in the next several months.
“We are seeing increasing interest in our embedded ESD solutions from multiple top tier companies and in products from cell phones, portable electronics, memory devices and semiconductors it has become evident we need to scale faster to meet the demand. Our investors have been both enthusiastic and sup- portive of the need to grow faster and support our customers due to the successes in our initial trials. Shocking will increase our staff 33% over the next
10-04 :: April 2010
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87